View source for US Patent Application 18028345. MULTIMERIC PROTEIN COMPLEXES AS ANTIBODY SUBSTITUTES FOR NEUTRALIZATION OF VIRAL PATHOGENS IN PROPHYLACTIC AND THERAPEUTIC APPLICATIONS simplified abstract

=MULTIMERIC PROTEIN COMPLEXES AS ANTIBODY SUBSTITUTES FOR NEUTRALIZATION OF VIRAL PATHOGENS IN PROPHYLACTIC AND THERAPEUTIC APPLICATIONS=


==Organization Name==

[[:Category:The Regents of the University of California|The Regents of the University of California]]


[[Category:The Regents of the University of California]]

==Inventor(s)==

[[:Category:Daniel L. Cox of San Francisco CA (US)|Daniel L. Cox of San Francisco CA (US)]][[Category:Daniel L. Cox of San Francisco CA (US)]]

[[:Category:Richard L. Davis of Penn Valley PA (US)|Richard L. Davis of Penn Valley PA (US)]][[Category:Richard L. Davis of Penn Valley PA (US)]]

[[:Category:Michael D. Toney of Davis CA (US)|Michael D. Toney of Davis CA (US)]][[Category:Michael D. Toney of Davis CA (US)]]

==MULTIMERIC PROTEIN COMPLEXES AS ANTIBODY SUBSTITUTES FOR NEUTRALIZATION OF VIRAL PATHOGENS IN PROPHYLACTIC AND THERAPEUTIC APPLICATIONS - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18028345 titled 'MULTIMERIC PROTEIN COMPLEXES AS ANTIBODY SUBSTITUTES FOR NEUTRALIZATION OF VIRAL PATHOGENS IN PROPHYLACTIC AND THERAPEUTIC APPLICATIONS

==Simplified Explanation==

The patent describes an engineered protein complex that can be used as a substitute for antibodies in treating viral infections, specifically COVID-19.

* The protein complex is made up of human proteins and has a specific symmetry.
* Each element of the protein complex contains a modified version of a human multimeric protein fused to a module containing multiple modified human beta solenoid proteins.
* The modified protein complex is also fused to a pathogen binding domain derived from humans.
* The patent also includes a separate antibody substitute composed of multiple pathogen binding domain complexes.
* The invention can be used in both preventive and therapeutic treatments for viral infections, particularly for neutralizing the SARS-CoV-2 virus.


==Original Abstract Submitted==

The present patent consists of an engineered multimeric protein complex as antibody substitute composed of human proteins, with an m-fold symmetry, with each m-fold element containing a modified monomeric protein derived from a symmetric human multimeric protein complex fused to a module containing n fused, modified human beta solenoid proteins (mBSP), and that fused to a human derived pathogen binding domain (PBD), as well as a separate antibody substitute composed of P human PBD complexes. The invention may find application in prophylactic and therapeutic treatments for viral infections, especially for COVID19 by neutralizing the SARS-CoV-2 virus.



[[Category:C07K16/10]]